| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $5.22B | +24.1% |
| Cost of Revenue | $3.10B | +32.0% |
| Gross Profit | $2.12B | +14.1% |
| R&D Expense | $233.4M | +22.0% |
| SG&A Expense | $203.8M | +8.2% |
| Operating Income | $1.60B | +14.5% |
| Pre-tax Income | $1.58B | +12.4% |
| Income Tax | $52.7M | -53.9% |
| Net Income | $1.53B |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $2.80B | +72.9% |
| Accounts Receivable | $1.29B | +2.6% |
| Inventory | $736.7M | -32.1% |
| Current Assets | $6.03B | +18.5% |
| Total Assets | $13.32B | +9.9% |
| Current Liabilities | $2.25B | +8.5% |
| Long-term Debt | $282.6M | -24.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $2.06B | +68.9% |
| Capital Expenditures | $869.9M | -43.0% |
| Investing Cash Flow | -$765.2M | +51.1% |
| Financing Cash Flow | -$119.2M | -579.8% |
| Free Cash Flow | $1.19B | +485.4% |
| +18.3% |
| EPS (Basic) | $14.25 | +18.1% |
| EPS (Diluted) | $14.21 | +18.2% |
| Total Liabilities |
| $3.78B |
| -8.8% |
| Stockholders' Equity | $9.54B | +19.6% |